f66ÓÀÀÖÖйú-Ñо¿Ö¤ÊµÈéÏÙ°©ÊõºóÑÓ³¤°¢ÄÇÇúßòÓÃҩʱ¼äÎÞ¶îÍâÊÕÒæ
2026-03-23 10:46:37
Ñо¿Ö¤Ã÷ÈéÏÙ°©ÊõºóÑÓÉì°¢ÄÇÇúßòÓÃҩʱ¼äÎÞ·ÖÍâÊÕÒæ
ÈÕÆÚ£º2021-09-16 À´Àú£º±¾Õ¾ ¹©¸å£ºÏÖ´úҽѧÓë´óÖÚÎÀÉú´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ
½üÆÚ£¬°ÂµØÀûάf66ÓÀÀÖÖйú-Ò²ÄÉÒ½¿ÆÄêҹѧ°©Ö¢ÖÐÑëµÄÑо¿ÍŶӷ¢Ã÷£¬¾ø¾ºó´Æ¼¤ËØÊÜÌåÑôÐÔµÄÈéÏÙ°©Êõºó»¼ÕßÑÓÉì°¢ÄÇÇúßò£¨Anastrozole£©µÄÀûÓÃÄêÏÞ²¢Î´Ôö³¤»¼ÕßÎÞ²¡±£´æÂÊ¡£¸ÃÑо¿ÓÚ¡¶The New England Journal of Medicine¡·ÉÏ·¢±í£¬ÌâΪ£ºDuration of AdjuvantAromatase-Inhibitor Therapy in Postmenopausal Breast Cancer¡£ °¢ÄÇÇúßò¾Óɹý³Ì°´Þà·Ò·¼»¯Ã¸µÄ»îÐÔ£¬×è¸ôÀ뾺óÅ®ÐԵĴƼ¤Ëغϳɣ¬´Ó¶ø°´Þ఩ϸ°ûÉú³¤¼°À©É¢£¬±»¹ã·ºÓÃÔÚ¾ø¾ºó´Æ¼¤ËØÊÜÌåÑôÐÔµÄÈéÏÙ°©Êõºó»¼Õ߸¨ÖúÒ½ÖΡ£±¾Ñо¿ÎªËæ»ú¡¢Ë«Ã¤¡¢±ÈÕÕ3ÆÚÁÙ´²ÊµÑ飬¹²ÄÉÈë3484Ãû»¼Õߣ¬Á¬ÐøËæ·Ã8Äê¡£³É¹ûÏÔʾ£¬Í¨ÀýÒ½ÖκóÁ¬ÐøÀûÓð¢ÄÇÇúßò2Äê×éÓë5Äê×éµÄÎÞ²¡±£´æÂÊÎÞÏÔÖø²îÒ죨73.6% vs 73.9%£©£¬×ܱ£´æÂÊÒàÎÞÏÔÖø²îÒ죨87.5% vs 87.3%£©£¬¶ÔÓÚ²àÈéÏÙ°©¡¢¼Ì·¢°©²¡·¢ÂÊÒÔºÍÑÇ×é²û·¢¾ùÎÞÏÔÖø²îÒ죻µ«Á¬ÐøÓÃÒ©5Äê×éµÄ¹ÇÕÛΣº¦¸ßÔÚ2Äê×飨6.3% vs 4.7%£©¡£ ¸ÃÑо¿³É¹û×¢½â£¬ÑÓÉì°¢ÄÇÇúßòÓÃÒ©ÄêÏÞ²¢Î´¸ø»¼Õß´øÀ´·ÖÍâÊÕÒæ£¬·´¶ø»áÔö³¤ÁÙ´²¹ÇÕÛΣº¦£¬ÎªÁÙ´²Ò½ÖξöÒ鼯»®ÌṩÁËÖ÷ÒªµÄÒÀ¾Ý¡£ ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶The New England Journal of Medicine¡·£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È¡£ ÔÎÄÁ´½Ó£ºhttps://www.nejm.org/doi/full/10.1056/NEJMoa2104162-f66ÓÀÀÖÖйú-

¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……
.png)
.jpg)